Since ameliorative effects are reported in several animal models of PKD [8–10, 45], PPAR-γ agonists are thought to be a potential candidate for therapeutic interventions in both ARPKD and ADPKD patients. Here, PPARG is linked to autosomal recessive polycystic kidney disease.